logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
E

Expert Opinion on Investigational Drugs

IF4.1
Papers3456
Citations5734
Journal Papers 3567
Publication Date
delete
Safety, pharmacokinetics, pharmacodynamics and target-mediated drug disposition modeling of TST002, a sclerostin antibody, in men and postmenopausal women with low bone mineral density
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-09-22
delete0
PREAI
deleteSufeng Zhou; Xiufen Zhu; Yuchen Sheng; Lu Wang; Feng Shao; Hua Lin
deleteShare
deleteSave
Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-09-20
delete0
PREAI
deleteCarlos Torrado; Anthony P. Conley
deleteShare
deleteSave
Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-09-12
delete0
deleteOAAI
deleteChi-Chen Sarah Huang; Cecilia Sanchez-Santos; Loreto Martinez-Gonzalez; Carmen Gil; Ana Martinez
deleteShare
deleteSave
Varespladib for snakebite envenoming: insights from therapeutic development and clinical trials
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-09-07
delete0
PREAI
deleteMadison R. McGann; Timothy F. Platts-Mills; Charles J. Gerardo
deleteShare
deleteSave
Up and coming early phase CAR T-cell therapy for treating relapsed or refractory large B-cell lymphoma
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-09-02
delete0
deleteOAAI
deleteDasom Lee; Masooma Rana; Arvin Esmali; Saurabh Dahiya
deleteShare
deleteSave
HLD-0915: Could it be the breakthrough drug we need for metastatic prostate cancer?
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-29
delete0
deleteOAAI
deleteJakob R. Nypaver; Pedro C. Barata
deleteShare
deleteSave
Peripheral cannabinoid-1 receptor antagonists in clinical development: therapeutic potential for the management of obesity and related metabolic disorders
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-21
delete0
deleteOAAI
deleteJonanne Talebloo; Esha Chawla; Donya Shahamati; Swas Shiv; Kishore M. Gadde
deleteShare
deleteSave
Taxane therapy in mCRPC: current positioning and emerging strategies to overcome resistance
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-20
delete0
PREAI
deleteLing Wang; Yanfeng Tang; Mingsheng Liu; Hongqing Zhou; Hao Zeng; Bo Tang
deleteShare
deleteSave
How can we determine suitable combination immunotherapies for cancer by looking at the molecular targeting of each therapy?
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-20
delete0
deleteOAAI
deleteNicole Sala; Giovanni Dalla Via; Giacomo De Micheli; Dario Trapani; Giuseppe Curigliano
deleteShare
deleteSave
Telisotuzumab adizutecan for metastatic colorectal cancer: a c-MET-targeted antibody–drug conjugate with a topoisomerase inhibitor payload
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-19
delete0
deleteOAAI
deleteYuki Matsubara; Akihito Kawazoe
deleteShare
deleteSave
Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-03
delete0
PREAI
deletePatricia Regina Manzine; Marina Carrasco; Thaís Antonia Alves Fernandes; Suelen Santos Alves; Laura Guzman; Leila Driouech; Mireia Millet-Sigalat; Norberto Garcia Cairasco; Jordi Olloquequi; M. Emilia Juan; Miren Ettcheto; Marcia Regina Cominetti; Antoni Camins
deleteShare
deleteSave
Budigalimab: a viable option for patients with advanced solid tumors
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-03
delete0
PREAI
deleteAlice Mogenet; Laurent Greillier
deleteShare
deleteSave
Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-07-29
delete0
deleteOAAI
deleteOsariemen Osunbor; Jan René Nkeck; Adewale O. Adebajo
deleteShare
deleteSave
Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-16
delete0
PREAI
deleteMarie Kroemer; Morgane Lopez; Laura Mansi; Elsa Curtit
deleteShare
deleteSave
Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-16
delete0
PREAI
deleteLuigi Francesco Iannone; Marina Romozzi; Luca Pani; Fabio Tascedda
deleteShare
deleteSave
The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-14
delete0
deleteOAAI
deleteStephen J. Walsh; Francesca Wood; Leslie R. DeMars; Gavin Bennett
deleteShare
deleteSave
Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-09
delete0
PREAI
deleteHui Qiu; Xingfei Zhang; Jie Huang; Lin Ye; Chan Zou; Jinlian Xie; Kunhong Deng; Qian Wu; Xiulin He; Congxin Liang; Yong Liu; Guang Yang; Guoping Yang; Chengxian Guo
deleteShare
deleteSave
The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-08
delete0
PREAI
deleteMatteo Bellia; Clara Deambrogi; Abdurraouf Mokhtar Mahmoud; Andrea Patriarca
deleteShare
deleteSave
Alpha-1 antitrypsin: therapeutic applications beyond serine protease inhibition
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-03
delete0
PREAI
deleteMartina Toldo; Trushaben Patel; Michele Golino; Eugenio Refrigeri; Jazmin Kelly; Antonio Abbate; Eleonora Mezzaroma; Stefano Toldo
deleteShare
deleteSave
SOT201: cis-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-03
delete0
PREAI
deleteVladyslav Mazhara; Irfan Baki Kilic; Irena Adkins; Radek Spisek; Marek Kovar
deleteShare
deleteSave